|
1
|
Latorzeff I, Ploussard G, Guillotreau J, Jonca F, Labarthe P, Rollin G, Beauval JB, Pathak A. [Cardiovascular risks with prostate cancer hormonal treatment: rationale for a department of oncocardiology]. Cancer Radiother 2016; 20:405-10. [PMID: 27344534 DOI: 10.1016/j.canrad.2016.02.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Revised: 02/19/2016] [Accepted: 02/24/2016] [Indexed: 11/16/2022]
Abstract
Prostate cancer, the most frequent cancer in man, is an adenocarcinoma sensible to chemical castration in more than 80% of cases due to its hormonal dependency. Androgen deprivation is the treatment for advanced cancer and can be associated with radiotherapy locally or in locally advanced situations. Multidisciplinary therapeutic choice depends on patient age and co-morbidities and clinical stage. The impact of hormonal treatment confers varied side effects and cardiovascular effects are now better known. Responsible mechanisms of this cardiotoxicity are at the same time direct but also indirect by metabolic thermogenic effects. Analysis of these clinical or biological effects, their correlations to the used type of hormonal treatment and the possible precautions of prescription will be detailed in this analysis of the literature. The collaboration of the oncologist or the urologist with the cardiologist becomes necessary and the existence of a unit of oncocardiology could improve the evaluation of the risk-benefit balance and the tolerance of the treatment.
Collapse
Affiliation(s)
- I Latorzeff
- Groupe Oncorad-Garonne, service d'oncologie-radiothérapie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France.
| | - G Ploussard
- Service d'urologie, clinique Saint-Jean-du-Languedoc, 20, route de Revel, 31400 Toulouse, France
| | - J Guillotreau
- Service d'urologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France
| | - F Jonca
- Service d'urologie, clinique Ambroise-Paré, 387, route de Saint-Simon, 31100 Toulouse, France
| | - P Labarthe
- Service d'urologie, clinique des Cèdres, château d'Alliez, 31700 Cornebarrieu, France
| | - G Rollin
- Service d'urologie, clinique d'Occitanie, 20, avenue Bernard-IV, 31600 Muret, France
| | - J-B Beauval
- Service d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France
| | - A Pathak
- Groupe Oncorad-Garonne, unité d'oncocardiologie, clinique Pasteur, bâtiment Atrium, 1, rue de la Petite-Vitesse, 31300 Toulouse, France; Service de cardiologie, clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France
| |
Collapse
|
|
2
|
Suivi après radiothérapie des cancers de prostate : évaluation et prise en charge de la toxicité et de la récidive. Cancer Radiother 2015; 19:582-9. [DOI: 10.1016/j.canrad.2015.05.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2015] [Accepted: 05/20/2015] [Indexed: 12/17/2022]
|
|
3
|
Quero L, Rozet F, Beuzeboc P, Hennequin C. The androgen receptor for the radiation oncologist. Cancer Radiother 2015; 19:220-7. [DOI: 10.1016/j.canrad.2015.02.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Revised: 02/01/2015] [Accepted: 02/04/2015] [Indexed: 01/11/2023]
|